Morgan Stanley Trims Y-mAbs Therapeutics (NASDAQ:YMAB) Target Price to $11.00

Y-mAbs Therapeutics (NASDAQ:YMAB) had its price target decreased by Morgan Stanley from $12.00 to $11.00 in a research report released on Tuesday, Benzinga reports. Morgan Stanley currently has an underweight rating on the stock.

Other equities research analysts have also issued reports about the stock. Wedbush restated an outperform rating and set a $23.00 target price on shares of Y-mAbs Therapeutics in a research report on Monday. BMO Capital Markets decreased their target price on shares of Y-mAbs Therapeutics from $26.00 to $25.00 and set an outperform rating on the stock in a research report on Tuesday. Truist Financial started coverage on shares of Y-mAbs Therapeutics in a research report on Friday, June 28th. They set a buy rating and a $21.00 target price on the stock. Finally, HC Wainwright restated a buy rating and set a $22.00 target price on shares of Y-mAbs Therapeutics in a research report on Tuesday. Two research analysts have rated the stock with a sell rating, five have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of Moderate Buy and a consensus price target of $19.29.

Y-mAbs Therapeutics Trading Up 2.0 %

Shares of YMAB opened at $12.21 on Tuesday. The company’s 50 day simple moving average is $11.84 and its 200-day simple moving average is $13.70. Y-mAbs Therapeutics has a 12-month low of $4.69 and a 12-month high of $20.90. The firm has a market cap of $535.81 million, a PE ratio of -24.92 and a beta of 0.66.

Y-mAbs Therapeutics (NASDAQ:YMAB) last posted its quarterly earnings data on Monday, August 12th. The company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.08). Y-mAbs Therapeutics had a negative net margin of 25.64% and a negative return on equity of 21.40%. The firm had revenue of $22.80 million during the quarter, compared to analysts’ expectations of $23.09 million. During the same quarter last year, the business earned ($0.14) earnings per share. As a group, equities research analysts forecast that Y-mAbs Therapeutics will post -0.52 EPS for the current fiscal year.

Insider Activity at Y-mAbs Therapeutics

In other Y-mAbs Therapeutics news, insider Thomas Gad sold 25,000 shares of Y-mAbs Therapeutics stock in a transaction dated Tuesday, May 21st. The stock was sold at an average price of $12.00, for a total value of $300,000.00. Following the completion of the sale, the insider now owns 240,032 shares in the company, valued at approximately $2,880,384. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other news, CFO Bo Kruse sold 31,371 shares of the business’s stock in a transaction dated Friday, May 31st. The stock was sold at an average price of $12.07, for a total transaction of $378,647.97. Following the completion of the sale, the chief financial officer now owns 210,877 shares in the company, valued at approximately $2,545,285.39. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Thomas Gad sold 25,000 shares of the business’s stock in a transaction dated Tuesday, May 21st. The stock was sold at an average price of $12.00, for a total value of $300,000.00. Following the sale, the insider now owns 240,032 shares of the company’s stock, valued at approximately $2,880,384. The disclosure for this sale can be found here. In the last quarter, insiders sold 99,444 shares of company stock valued at $1,203,925. 21.50% of the stock is owned by insiders.

Institutional Trading of Y-mAbs Therapeutics

A number of institutional investors have recently modified their holdings of the company. Millennium Management LLC boosted its holdings in Y-mAbs Therapeutics by 23.8% in the 2nd quarter. Millennium Management LLC now owns 349,784 shares of the company’s stock worth $4,225,000 after acquiring an additional 67,233 shares during the period. Squarepoint Ops LLC boosted its holdings in Y-mAbs Therapeutics by 143.4% in the 2nd quarter. Squarepoint Ops LLC now owns 126,389 shares of the company’s stock worth $1,527,000 after acquiring an additional 74,452 shares during the period. XTX Topco Ltd purchased a new position in Y-mAbs Therapeutics in the 2nd quarter worth approximately $297,000. Dimensional Fund Advisors LP boosted its holdings in Y-mAbs Therapeutics by 15.7% in the 2nd quarter. Dimensional Fund Advisors LP now owns 484,431 shares of the company’s stock worth $5,853,000 after acquiring an additional 65,732 shares during the period. Finally, Massachusetts Financial Services Co. MA boosted its holdings in Y-mAbs Therapeutics by 3.5% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 82,202 shares of the company’s stock worth $993,000 after acquiring an additional 2,760 shares during the period. Hedge funds and other institutional investors own 70.85% of the company’s stock.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.